

SIGN 135: Management of epithelial ovarian cancer

Review report

Date	Update request	Decision	Status	Description
03/10/2017	Incorporate evidence on PARP inhibitors	Update	Published June 2018	New evidence on the use of PARP inhibitors in patients with recurrent ovarian cancer has been added to section 6.3.1
07/06/2016	<p>New advice on the use of bevacizumab for patients with platinum-resistant recurrent epithelial ovarian cancer was published by SMC in 2015.</p> <p>A NICE MTA was published in April 2016 which does not recommend gemcitabine in combination with carboplatin for treating first recurrence.</p> <p>The guideline should be updated to incorporate this new advice.</p>	Update	Published June 2018	<p>The evidence statement has been updated in section 6.2.5 and a new recommendation for the use of bevacizumab in combination with carboplatin and paclitaxel in women with stage IV ovarian cancer has been added.</p> <p>The evidence statement in section 6.3.1 have been revised to incorporate the new evidence on combination therapies for women with recurrent ovarian cancer. The recommendation has been replaced with three new recommendations on combination therapies.</p>
13/08/2018	<p>Advice on the use of niraparib as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy was published by the SMC.</p> <p>The guideline already has a statement on the clinical efficacy of niraparib. It should be updated to incorporate the SMC advice and a recommendation on use.</p>	Update	Published October 2018	A recommendation on the use of niraparib has been added to section 6.3.1